Floatz logo

gsk1120212

Recurrent Extrahepatic Bile Duct Carcinoma

National Cancer Institute (NCI)Phase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Recurrent Extrahepatic Bile Duct Carcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Lisata Therapeutics, Inc.
Phase 2BBB
Eloxatin
Lisata Therapeutics, Inc.
Phase 3BBB
Capecitabine
National Cancer Institute (NCI)
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Lisata Therapeutics, Inc.
Phase 2BB
Irinotecan
AIO-Studien-gGmbH
Phase 2BB

View all 47 →

Same molecule, other indications

gsk1120212 is also rated in:

anaplastic pleomorphic xanthoastrocytomaDormant
BB
Indicative ·
69 / 100
View asset →
Glioma, High GradeDormant
BB
Indicative ·
69 / 100
View asset →
anaplastic oligodendrogliomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →